NCT03293732View on ClinicalTrials.gov

Study of the Safety, Tolerability and Immunogenicity of an Intranasal Influenza Vaccine Administered to Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 28, 2012

Primary Completion Date

March 30, 2013

Study Completion Date

September 30, 2013

Conditions
Flu, Human
Interventions
BIOLOGICAL

DCB07010

A protein based adjuvant originated from prokaryotic organism.

BIOLOGICAL

HA antigens

HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).

Trial Locations (1)

10002

National Taiwan Univserity Hospital, Taipei

All Listed Sponsors
collaborator

National Taiwan University Hospital

OTHER

lead

Advagene Biopharma Co. Ltd.

INDUSTRY

NCT03293732 - Study of the Safety, Tolerability and Immunogenicity of an Intranasal Influenza Vaccine Administered to Healthy Adults | Biotech Hunter | Biotech Hunter